Yuji

NIO Could Fail In FQ2 2022 - But The Patient May Be Rewarded By H2 2022

Investment ThesisIt is evident that NIO Inc. (NYSE:NIO) will face a challenging YoY comparison from
NIO Could Fail In FQ2 2022 - But The Patient May Be Rewarded By H2 2022

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论1

  • 推荐
  • 最新
empty
暂无评论